Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS MUTATION
KRAS MUTATION - Associated Disease
- ovarian cancer
- Source Database
- CIViC Evidence
- Description
- KRAS mutation or amplification predicted sensitivity to decitabine in ovarian cancer cell lines. The authors profiled the response of 45 ovarian, melanoma, and breast cancer cell lines over 9 days of treatment with decitabine. 4 ovarian lines with KRAS mutation were among the most sensitive to decitabine.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/820
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/336
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Ovarian Cancer
- Evidence Direction
- Supports
- Drug
- Decitabine
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25968887
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Decitabine | Sensitivity | true |